BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 14565510)

  • 1. Single-agent chemotherapy for non-small cell lung cancer.
    Eckardt J
    Lung Cancer; 2003 Aug; 41 Suppl 4():S17-22. PubMed ID: 14565510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly topotecan in the management of lung cancer.
    Treat J
    Lung Cancer; 2003 Aug; 41 Suppl 4():S27-31. PubMed ID: 14565512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the role of topotecan in the treatment of non-small cell lung cancer.
    Stewart DJ
    Oncologist; 2004; 9 Suppl 6():43-52. PubMed ID: 15616149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents.
    Meoni G; Cecere FL; Lucherini E; Di Costanzo F
    J Geriatr Oncol; 2013 Jul; 4(3):282-90. PubMed ID: 24070465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine.
    Stupp R; Bodmer A; Duvoisin B; Bauer J; Perey L; Bakr M; Ketterer N; Leyvraz S
    Oncology; 2001; 61 Suppl 1():35-41. PubMed ID: 11598413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Topotecan, a recent discovery and prospects for treating tumors of the lung].
    Gridelli C
    Tumori; 1999; 85(6 Suppl 1):S16-22. PubMed ID: 10786196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer.
    Pujol JL; von Pawel J; Tumolo S; Martoni A; Hearn S; Fields SZ; Ross G
    Oncology; 2001; 61 Suppl 1():47-54. PubMed ID: 11598415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status.
    Ikeda S; Yoshioka H; Ikeo S; Morita M; Sone N; Niwa T; Nishiyama A; Yokoyama T; Sekine A; Ogura T; Ishida T
    BMC Cancer; 2017 Nov; 17(1):797. PubMed ID: 29183294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
    Seung SK; Ross HJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):802-9. PubMed ID: 18762390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsmall cell lung cancer.
    Aggarwal C; Langer CJ
    Curr Opin Oncol; 2012 Mar; 24(2):130-6. PubMed ID: 22314616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
    Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy.
    Socinski MA
    Clin Lung Cancer; 2004 Mar; 5(5):274-89. PubMed ID: 15086966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan in the treatment of recurrent small cell lung cancer: an update.
    Ardizzoni A
    Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan in the treatment of non-small cell lung cancer.
    Perez-Soler R
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-34-S20-41. PubMed ID: 9425959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current standards of care in small-cell and non-small-cell lung cancer.
    Schiller JH
    Oncology; 2001; 61 Suppl 1():3-13. PubMed ID: 11598409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of disease as an indicator of clinical benefit associated with chemotherapy in non-small cell lung cancer patients.
    Cesano A; Lane SR; Ross GA; Fields SZ
    Int J Oncol; 2000 Sep; 17(3):587-90. PubMed ID: 10938402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for advanced non-small cell lung cancer: standards.
    Manegold C
    Lung Cancer; 2001 Dec; 34 Suppl 2():S165-70. PubMed ID: 11720760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy versus single agent chemotherapy in non-small cell lung cancer.
    Cheong K; Spicer J; Chowdhury S; Harper P
    Expert Opin Pharmacother; 2005 Aug; 6(10):1693-700. PubMed ID: 16086655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent topics in chemotherapy for elderly patients with lung cancer].
    Okamoto H; Watanabe K
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1097-104. PubMed ID: 10945002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.